ATE314097T1 - Kontrastmittel - Google Patents

Kontrastmittel

Info

Publication number
ATE314097T1
ATE314097T1 AT97910516T AT97910516T ATE314097T1 AT E314097 T1 ATE314097 T1 AT E314097T1 AT 97910516 T AT97910516 T AT 97910516T AT 97910516 T AT97910516 T AT 97910516T AT E314097 T1 ATE314097 T1 AT E314097T1
Authority
AT
Austria
Prior art keywords
angiotensin
line
formulae
sup
matter
Prior art date
Application number
AT97910516T
Other languages
English (en)
Inventor
Jo Klaveness
Anne Naevestad
Alan Cuthbertson
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622367.2A external-priority patent/GB9622367D0/en
Priority claimed from GBGB9622365.6A external-priority patent/GB9622365D0/en
Priority claimed from GBGB9622364.9A external-priority patent/GB9622364D0/en
Priority claimed from GBGB9622366.4A external-priority patent/GB9622366D0/en
Priority claimed from GBGB9622369.8A external-priority patent/GB9622369D0/en
Priority claimed from GBGB9622368.0A external-priority patent/GB9622368D0/en
Priority claimed from GBGB9700699.3A external-priority patent/GB9700699D0/en
Priority claimed from GBGB9702195.0A external-priority patent/GB9702195D0/en
Priority claimed from GBGB9706063.6A external-priority patent/GB9706063D0/en
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE314097T1 publication Critical patent/ATE314097T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT97910516T 1996-10-28 1997-10-28 Kontrastmittel ATE314097T1 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9622367.2A GB9622367D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622365.6A GB9622365D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622364.9A GB9622364D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622366.4A GB9622366D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622369.8A GB9622369D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9622368.0A GB9622368D0 (en) 1996-10-28 1996-10-28 Improvements in or relating to diagnostic/therapeutic agents
GBGB9700699.3A GB9700699D0 (en) 1997-01-15 1997-01-15 Improvements in or relating to diagnostic/therapeutic agents
GBGB9702195.0A GB9702195D0 (en) 1997-02-04 1997-02-04 Improvements in or relating to diagnostic/therapeutic agents
GBGB9706063.6A GB9706063D0 (en) 1997-03-24 1997-03-24 Contrast agents
US5824797P 1997-09-09 1997-09-09
PCT/GB1997/002956 WO1998018496A2 (en) 1996-10-28 1997-10-28 Contrast agents

Publications (1)

Publication Number Publication Date
ATE314097T1 true ATE314097T1 (de) 2006-01-15

Family

ID=27579412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910516T ATE314097T1 (de) 1996-10-28 1997-10-28 Kontrastmittel

Country Status (5)

Country Link
US (4) US6264914B1 (de)
EP (1) EP0971747B1 (de)
AT (1) ATE314097T1 (de)
ES (1) ES2257771T3 (de)
WO (1) WO1998018496A2 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257771T3 (es) * 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7139122B1 (en) * 2000-10-17 2006-11-21 Lucid, Inc. System and method for enhancing confocal reflectance images of tissue specimens
US7003345B1 (en) * 2000-10-17 2006-02-21 Lucid, Inc. System and method for enhancing microscope images of tissue using citric acid and agents of the like
US6631283B2 (en) * 2000-11-15 2003-10-07 Virginia Tech Intellectual Properties, Inc. B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
US7198945B2 (en) * 2001-08-09 2007-04-03 Teruyuki Nagamune Cell having modified cell membrane
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
JP2006514915A (ja) 2002-03-01 2006-05-18 ダイアックス、コープ Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP1587944A4 (de) 2002-03-01 2007-03-21 Dyax Corp Kdr und vegf/kdr-bindende peptide und ihre diagnostische und therapeutische veranwendung bei der diagnose und therapie
US20040133112A1 (en) * 2002-03-08 2004-07-08 Milind Rajadhyaksha System and method for macroscopic and confocal imaging of tissue
US6933399B2 (en) * 2002-05-02 2005-08-23 The University Of Connecticut Functionalized metal complexes
EP1517684B1 (de) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP2036908A3 (de) * 2002-07-02 2009-05-13 Health Research, INC. Effiziente Synthese von Pyropheophorbid-A-Derivaten
US7410683B2 (en) * 2002-12-20 2008-08-12 The Procter & Gamble Company Tufted laminate web
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
EP1593091B1 (de) * 2003-01-25 2013-07-17 Seno Medical Instruments, Inc. Optoakustische Bildgebung mit hohem Kontrast mit Hilfe von nicht-sphärischen Nanopartikeln
EP1947116B1 (de) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
SI2949658T1 (sl) 2003-03-03 2018-10-30 Dyax Corp. Peptidi, ki specifično vežejo HGF receptor (cMet) in njihove uporabe
US20040258760A1 (en) * 2003-03-20 2004-12-23 Wheatley Margaret A. Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
US20060239913A1 (en) * 2003-06-25 2006-10-26 Marc Port Peptide conjugate for magnetic resonance imaging
WO2005044313A2 (en) * 2003-11-06 2005-05-19 Amersham Health As Conjugates of angiotensin ii and an imaging moiety
WO2005049095A2 (en) 2003-11-24 2005-06-02 Amersham Health As Contrast agent imaging angiotensin ii receptors
ITMI20032338A1 (it) * 2003-11-28 2005-05-29 Dinamite Dipharma S P A In Forma A Bbreviata Diph Composti feniltetrazolici.
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
AU2005219413A1 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
WO2005084715A2 (en) * 2004-03-04 2005-09-15 Ge Healthcare As Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
KR100562050B1 (ko) * 2004-03-30 2006-03-17 한국화학연구원 가교된 폴리비닐알콜계 신규 고분자막 및 이의 제조방법
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20080095704A1 (en) * 2004-07-02 2008-04-24 Alan Cuthbertson Imaging Agents with Improved Pharmacokinetic Profiles
AU2005307195A1 (en) 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
US7902282B2 (en) * 2005-04-28 2011-03-08 Api Corporation Pressure-sensitive adhesive containing near infrared absorbing coloring matter
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US8518069B2 (en) 2005-09-07 2013-08-27 Cabochon Aesthetics, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US10548659B2 (en) 2006-01-17 2020-02-04 Ulthera, Inc. High pressure pre-burst for improved fluid delivery
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
WO2007042504A2 (fr) * 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP2009512696A (ja) * 2005-10-20 2009-03-26 セントカー・インコーポレーテツド 標的化イムノリポソームの調製法
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9248317B2 (en) * 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US7885793B2 (en) 2007-05-22 2011-02-08 International Business Machines Corporation Method and system for developing a conceptual model to facilitate generating a business-aligned information technology solution
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
CA2631716C (en) 2005-12-09 2013-11-26 Bracco International B.V. Targeting vector-phospholipid conjugates
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US9259398B1 (en) * 2007-11-26 2016-02-16 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded targeting micelles
EP2147684A1 (de) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
JP2011529072A (ja) * 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
WO2010107832A1 (en) 2009-03-17 2010-09-23 Bracco Imaging Spa Lhrh-ii peptide analogs
CN102356087A (zh) 2009-03-19 2012-02-15 惠氏有限责任公司 [2-(8,9-二氧代-2,6-二氮杂双环[5.2.0]壬-1(7)-烯-2-基)乙基]膦酸及其前体的制备方法
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
US11096708B2 (en) 2009-08-07 2021-08-24 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
SI2547364T1 (sl) 2010-03-15 2017-05-31 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptidi, konjugati in postopek za povečanje imunogenosti cepiva
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
ES2651113T3 (es) 2012-06-25 2018-01-24 The Brigham And Women's Hospital, Inc. Tratamientos terapéuticos dirigidos
AU2013363398B2 (en) 2012-12-20 2017-06-01 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
EP2968470B1 (de) 2013-03-12 2020-10-28 The General Hospital Corporation Modifizierte proteine mit einer müllerschen hemmersubstanz und verwendungen davon zur behandlung von krankheiten
EA201690230A1 (ru) 2013-09-06 2016-07-29 Инсепшн 2, Инк. Соединения триазолона и их применения
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
DK3079712T3 (da) 2013-12-11 2022-04-25 Massachusetts Gen Hospital Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
CN107624115B (zh) 2015-03-16 2021-10-26 加州理工学院 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
EP3322716A2 (de) 2015-07-15 2018-05-23 California Institute of Technology Il-17f-spezifische einfänger, zusammensetzungen und verfahren zur verwendung und herstellung
WO2017059226A1 (en) * 2015-10-02 2017-04-06 The Johns Hopkins University Supramolecular hydrogels containing angiotensin receptor blockers for targeted treatment of diabetic wounds
EP3440101B1 (de) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-spezifische einfänger, zusammensetzungen und verfahren zur verwendung und herstellung davon
AR108906A1 (es) 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
US11358982B2 (en) 2016-11-01 2022-06-14 Ohio State Innovation Foundation Methods for the iodination of biomolecules
EP3638687A1 (de) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f- und il-17a-spezifische fänger, zusammensetzungen und verfahren zur verwendung und herstellung davon
EP3768299A1 (de) 2018-03-22 2021-01-27 The Children's Medical Center Corporation Verfahren und zusammensetzungen im zusammenhang mit der lungenreparatur
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
WO2020186091A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
GB201917699D0 (en) 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates
BR112022022045A2 (pt) 2020-04-30 2023-01-10 Sairopa B V Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd103 humano, um ou mais ácidos nucleicos, sistema de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou fragmento de ligação ao antígeno, para detectar a presença de cd103 em uma amostra biológica, para tratar ou prevenir uma condição mediada por sinalização de cd103 em um indivíduo em necessidade, para inibir a sinalização de cd103 em uma célula, para inibir a ligação de cd103 à e-caderina presente em uma célula, para retirar as células que expressam cd103 em um indivíduo, para tratar ou prevenir uma doença e agente de imageamento
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2024074666A1 (en) 2022-10-06 2024-04-11 Mireca Medicines Gmbh Conjugates for neuroretinal drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411881A (en) * 1982-07-12 1983-10-25 New England Nuclear Corporation Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
IN172208B (de) * 1990-04-02 1993-05-01 Sint Sa
JP3208139B2 (ja) * 1990-10-02 2001-09-10 ワーナー−ランバート・コンパニー アンギオテンシン▲ｉｉ▼アンタゴニスト
US5780010A (en) * 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
JPH09165378A (ja) * 1995-12-15 1997-06-24 Seitai Kinou Kenkyusho:Kk Ｎ１−［１８ｆ］フルオロベンジル複素環化合物およびそれらの製造法
JPH09165377A (ja) * 1995-12-15 1997-06-24 Seitai Kinou Kenkyusho:Kk 新規２−フルオロ芳香環−ｎ１置換イミダゾール化合物およびその［１８ｆ］フッ素標識体
ES2257771T3 (es) * 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.

Also Published As

Publication number Publication date
WO1998018496A2 (en) 1998-05-07
WO1998018496A3 (en) 1998-07-16
EP0971747A2 (de) 2000-01-19
US6524552B2 (en) 2003-02-25
ES2257771T3 (es) 2006-08-01
US20050201930A1 (en) 2005-09-15
US7182934B2 (en) 2007-02-27
US20010016587A1 (en) 2001-08-23
US6921525B2 (en) 2005-07-26
EP0971747B1 (de) 2005-12-28
US6264914B1 (en) 2001-07-24
US20030228254A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
ATE314097T1 (de) Kontrastmittel
WO1998018497A3 (en) Contrast agents
GB9708265D0 (en) Contrast agents
ATE395938T1 (de) Mittel auf basis radiomarkierter peptide zur ortsspezifischen verabreichung
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
FI911319A0 (fi) Polypeptidderivat.
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
DK0640622T3 (da) Polysaccharidderivat og lægemiddelbærer
HUP0004394A2 (hu) Egyláncú bifunkcionális glikoprotein hormonok
IL182898A0 (en) Contrast agents
DE69419919D1 (de) Technetium-99m markierte peptide zur bilderzeugung der entzuendung
DE69728529D1 (de) Cytokinantagonisten und -agonisten
DE69221486D1 (de) Bombesinanaloge
SE9700934D0 (sv) New formulation
ATE425770T1 (de) Kontrastmittel
HUP9904547A3 (en) Benzoxazole derivative with an affinity to binding sites of amino acid receptors and pharmaceutical compositions containing the same
WO2000078796A3 (en) Labeled neurotensin derivatives with improved resistance to enzymatic degradation
DK0478631T3 (da) Målsøgende midler
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
WO2005049095A3 (en) Contrast agent imaging angiotensin ii receptors
WO2000031123A3 (en) Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
ATE287733T1 (de) Spinresonanz kontrastmittel für das blut
MA25414A1 (fr) Amides d'acide carboxylique de phenylcyclohexane qui ont un effet inhibiteur de fixation d'adenosine.
ES2150974T3 (es) Terminal de dispositivo de deteccion de desgaste de guarnicion de friccion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties